Expediting hit-to-lead progression in drug discovery through reaction prediction and multi-dimensional optimization

D David F. Nippa K Kenneth Atz Y Yannick Stenzhorn A Alex T. Müller A Andreas Tosstorff J Jörg Benz (Roche Pharma Research & Early Development) H Hayley Binch M Markus Bürkler A Achi Haider D Dominik Heer (Roche Pharma Research & Early Development) R Remo Hochstrasser (Roche Pharma Research & Early Development) C Christian Kramer M Michael Reutlinger P Petra Schneider T Thierry Shema A Andreas Topp (Roche Pharma Research & Early Development) A Alexander Walter M Matthias B. Wittwer J Jens Wolfard B Bernd Kuhn M Mario van der Stelt (Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research) R Rainer E. Martin U Uwe Grether (Roche Pharma Research & Early Development) G Gisbert Schneider

Abstract

Abstract The rapid and economical synthesis of novel bioactive compounds remains a hurdle in drug discovery efforts. This study demonstrates an integrated medicinal chemistry workflow that effectively diversifies hit and lead structures, enabling an acceleration of the critical hit-to-lead optimization phase. Employing high-throughput experimentation (HTE), we generated a comprehensive data set encompassing 13,490 novel Minisci-type C-H alkylation reactions. These data served as the foundation for training deep graph neural networks to accurately predict reaction outcomes. Scaffold-based enumeration of potential Minisci reaction products, starting from moderate inhibitors of monoacylglycerol lipase (MAGL), yielded a virtual library containing 26,375 molecules. This virtual chemical library was evaluated using reaction prediction, physicochemical property assessment, and structure-based scoring, identifying 212 MAGL inhibitor candidates. Of these, 14 compounds were synthesized and exhibited subnanomolar activity, representing a potency improvement of up to 4500 times over the original hit compound. These ligands also showed favorable pharmacological profiles. Co-crystallization of three computationally designed ligands with the MAGL protein provided structural insights into their binding modes. This study demonstrates the potential of combining miniaturized HTE with deep learning and optimization of molecular properties to reduce cycle times in hit-to-lead progression.

Article Details

Volume / Issue Vol. 16, Issue 1
Published November 26, 2025
ISSN 2041-1723
Publisher Nature Portfolio

Journal Info

Nature Communications

Nature Portfolio

ISSN: 2041-1723 Open Access Life Sciences

Authors (24)

D

David F. Nippa

K

Kenneth Atz

Y

Yannick Stenzhorn

A

Alex T. Müller

A

Andreas Tosstorff

J

Jörg Benz

Roche Pharma Research & Early Development

H

Hayley Binch

M

Markus Bürkler

A

Achi Haider

D

Dominik Heer

Roche Pharma Research & Early Development

R

Remo Hochstrasser

Roche Pharma Research & Early Development

C

Christian Kramer

M

Michael Reutlinger

P

Petra Schneider

T

Thierry Shema

A

Andreas Topp

Roche Pharma Research & Early Development

A

Alexander Walter

M

Matthias B. Wittwer

J

Jens Wolfard

B

Bernd Kuhn

M

Mario van der Stelt

Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research

R

Rainer E. Martin

U

Uwe Grether

Roche Pharma Research & Early Development

G

Gisbert Schneider